BRTX BioRestorative: Nilai Akuntansi saben Saham
A high dependence on external logistics and medical contractors is accelerating the development of the BRTX-100 drug for BioRestorative Therapies (BRTX), confirming the absolute level of the stock's book value, which currently stands at 2.40. The strategy is completed by a bet on personalized medicine and the therapy of metabolic disorders, creating a solid foundation for the long-term growth of the company's capitalization.
BioRestorative Therapies Inc - rincian analitis lan metrik utama (BRTX)
The visualization of the book value per share reflects the status of BioRestorative Therapies (BRTX) as a biotech startup heavily dependent on the success of the BRTX-100 drug. This indicator is calculated as the difference between all company assets and liabilities divided by the number of shares, allowing for an assessment of the real value of an investor's stake and capital stability while awaiting clinical trial results.